비영어권 저자들을 위한 학술 논문출간 영문교정 서비스

Global Reach

번역샘플 - 의약연구학 (Pharmaceutical Research)

품질 및 시기 적절한 투고물을 제공하는 것은 급선무로 특히 조절 의뢰의 경우 더욱 필요하다.

이나고는 주제별 전문가 리뷰어, 번역가, 저자, 교정자로 이루어진 특별한 팀과 함께 더불어 귀하의 언어로 24 시간 전문 프로젝트 관리자를 제공함으로써 정시에 고품질의 투고물을 제공합니다. 저희는 단어 대 단어 번역을 뛰어 넘어 최첨단 기술과 엄격한 프로세스를 통해 귀하의 주제 영역의 뉘앙스까지 살린 고품질 번역을 제공합니다.

아래는 저희의 우수한 번역본의 샘플들입니다.

목적: 복합 이상지혈증을 치료하는 현행 임상 지침에서는 페노피브레이트와 스타틴의 복합 치료법을 적극적으로 권장하고 있다. 본 연구에서는 페노피브레이트의 약동학적 프로파일을 변경함으로써 이 복합요법의 동시 투여로 발생할 수 있는 근육 독성 위험을 줄이고, 변경된 방출 포뮬레이션에서 경구 투여 시 생체 이용률을 개선하기 위하여 페노피브레이트의 혁기적인 지연 방출 제제 포뮬레이션을 만들었다.

방법: 다분자 펠릿 코팅을 하기 전, 분말 층화 과정을 통해 약물 적재 코어를 준비하기 위하여 페노피브레이트를 미립자화 시켰다. 연구진은 다양한 코팅 포뮬레이션을 검토하였고, 시험관 내(in vitro) 방출 프로파일은 상업용 지속 방출 제제 펠릿 Lipilfen(리필펜)과 비교하였다. 그중 가장 최적화된 두 가지 포뮬레이션을 비글을 대상으로 평가하였고, 페노피브레이트 레퍼런스 시판 제제인 즉시 방출 제제인 Lipanthyl®과 지속 방출 펠릿인 Lipilfen®을 비교하였다.

결과: 시험관 내 시험에서 선택한 R1 및 R2의 체내 페노피브레이트 방출은 유도기를 보인 후 신속하고 완전한 약물 방출을 나타냈다. R1과 R2의 상대 생체 이용률은 Lipilfen® (67.2%)보다 높은 100.4%와 201.1%로 각각 나타났다.

결론: 변경된 페노피브레이트는 향상된 생체 이용률과 지연 방출 제제의 특성을 보였으며, 스타틴과 함께 복합 투여될 때 안전성과 순응도를 잠재적으로 개선할 수 있다. 이는 우리가 아는 바로는, 페노피브레이트에 대한 지연 방출 제제에 대한 최초의 연구 결과이다.

Purpose: Fenofibrate and statin combination therapy is highly recommended by the current clinical guidelines for treatment of combined dyslipidemia. In this study, an innovative delayed-release preparation of fenofibrate was designed to reduce the risk of muscle toxicity, caused by simultaneous administration of this combination therapy, by altering the pharmacokinetic profile of fenofibrate, as well as to improve the oral bioavailability of the modified-release formulation.

Methods: Micronized fenofibrate was used to prepare drug-loaded cores via a powder layering process before multiparticulate pellet coating. Different coating formulations were screened, and their in vitro release was compared with the commercial sustained-release pellets Lipilfen®. Two optimized formulations were evaluated in Beagle dogs using two commercial preparations of fenofibrate (the immediate release preparation Lipanthyl® and the sustained release pellets Lipilfen®) as references.

Results: The in vivo release of fenofibrate from R1 and R2 selected from in vitro tests exhibited a lag phase, and then rapid and complete drug release. The relative bioavailabilities of R1 and R2 were 100.4% and 201.1%, respectively, which were greater than that of Lipilfen® (67.2%).

Conclusion: The modified fenofibrate pellets developed enhanced bioavailability and delayed-release properties. They have the potential to improve safety and compliance when co-administrated with statins. This is the first report of a delayed-release fenofibrate preparation.

Purpose: Combination therapy of Ffenofibrate and statins combination therapy is highly recommended by the current clinical guidelines for the 1treatment of combinedmixed2 dyslipidemia. In this study, we formulated 3an innovative delayed-release preparation of fenofibrate was designed to achieve the following: to reduce the risk of muscle toxicity, caused by simultaneous administration of this combination therapy, by altering the pharmacokinetic profile of fenofibrate, as well as to improve the oral bioavailability of the modified-release formulation.

Methods: Micronized fFenofibrate was usedmicronized to prepare drug-loaded cores via a powder layering process before multiparticulate pellet coating. Different coating formulations were screened, and their in vitro release profiles was compared with the commercial sustained-release pellets Lipilfen®. Two optimized formulations were evaluated in Beagle dogs using and compared with 4two commercial preparations of fenofibrate (the immediate release preparation Lipanthyl® and the sustained release pellets Lipilfen®) as references.

Results: The in vivo release of fenofibrate from R1 and R2 selected from in vitro tests exhibited a lag phase, and thenfollowed by 5rapid and complete drug release. The relative bioavailabilities of R1 and R2 were 100.4% and 201.1%, respectively, which were greater than that of Lipilfen® (67.2%).

Conclusion: The modified fenofibrate pellets developed showed enhanced bioavailability and delayed-release properties. They have the potential to improve safety and compliance when co-administratedadministered 6with statins. This is the first report of a delayed-release fenofibrate preparation.

  1. [문법] 관사를 추가했습니다.
  2. [전문용어 선택] [전문분야] 문헌과 부합하는 올바른 전문용어가 사용되었습니다.
  3. [정확성] 더 정확한 단어를 선택했습니다.
  4. [오역] 사소한 오역을 수정했습니다.
  5. [단어 선택] 명확성을 높이기 위해 더 나은 단어를 선택했습니다.
  6. [철자] [언어] 사소한 철자 오류를 수정했습니다.

Purpose: Combination1According to current guidelines.combination therapy of Ffenofibrate and statins combination therapy is highly recommended by the current clinical guidelines for the 2treatment oftreating combinedmixed3 dyslipidemia. In this study, we formulated 4an innovative delayed-release preparation of fenofibrate was designed to achieve the following: to reduce the risk of muscle toxicity, caused by simultaneous administration of this combination therapy, by altering the pharmacokinetic profile of fenofibrate, as well asand to improve the oral bioavailability of the modified-release formulation.

Methods: Micronized fFenofibrate was usedmicronized and used to prepare drug-loaded cores via a powder-5layering process before performing 6multiparticulate pellet coating. Different coating formulations were screened, and their in vitro release profiles waswere compared with those of the commercial sustained-release pellets Lipilfen®. Two optimized formulations were evaluated in Beagle dogs using7 models and compared with two reference commercial preparations of fenofibrate (, Lipanthyl®(the immediate-release preparation Lipanthyl®) and Lipilfen®(the sustained-release pellets Lipilfen®) as references).

Results: The in vivo release of fenofibrate from R1 and R2 (selected from in vitro tests) exhibited a lag phase, and thenwhich was followed by 8rapid and complete drug release. The relative bioavailabilities of R1 and R2 were 100.4% and 201.1%, respectively, which were greater9were higher than that of Lipilfen® (67.2%).

Conclusion: The modifiedModified fenofibrate pellets developed showed enhanced bioavailability and delayed-release properties. They have the potential toproperties and can improve safety and compliance when co-administratedadministered10 with statins. This To the best of our knowledge, this is the first report of a delayed-release preparation of fenofibrate preparation11.

  1. [가독성] 쉽게 읽히도록 표현을 개선했습니다.
  2. [문법] 관사를 추가했습니다.
  3. [전문용어 선택] [전문분야] 문헌과 부합하는 올바른 전문용어가 사용되었습니다.
  4. [정확성] 더 정확한 단어를 선택했습니다.
  5. [구두점] 복합 수식어의 의미를 명확하게 전달하기 위해 하이픈을 추가했습니다.
  6. [명확성] 쉽게 이해할 수 있도록 추가했습니다.
  7. [오역] 사소한 오역을 수정했습니다.
  8. [단어 선택] 명확성을 높이기 위해 더 나은 단어를 선택했습니다.
  9. [단어 선택] 더 정확한 단어를 선택했습니다.
  10. [철자] [언어] 사소한 철자 오류를 수정했습니다.
  11. [일관성] [스타일] 본문(“Purpose” 아래)에서 이전에 사용된 표현과 일관성을 유지하기 위해 표현을 수정했습니다.

Purpose: According to current guidelines.combination therapy of fenofibrate and statins is highly recommended for treating mixed dyslipidemia. In this study, we formulated an innovative delayed-release preparation of fenofibrate to reduce the risk of muscle toxicity, by altering the pharmacokinetic profile of fenofibrate and to improve the oral bioavailability of the modified-release formulation.

Methods: Fenofibrate was micronized and used to prepare drug-loaded cores via a powder-layering process before performing multiparticulate pellet coating. Different coating formulations were screened, and their in vitro release profiles were compared with those of the commercial sustained-release pellets Lipilfen®. Two optimized formulations were evaluated in Beagle dogs models and compared with two reference commercial preparations of fenofibrate, Lipanthyl®(the immediate-release preparation) and Lipilfen®(the sustained- release pellets) .

Results: The in vivo release of fenofibrate from R1 and R2 (selected from in vitro tests) exhibited a lag phase, which was followed by rapid and complete drug release. The relative bioavailabilities of R1 and R2 were 100.4% and 201.1%, respectively, which werehigher than that of Lipilfen® (67.2%).

Conclusion: Modified fenofibrate pellets showed enhanced bioavailability and delayed-release propertiesand can improve safety and compliance when co-administered with statins. To the best of our knowledge, this is the first report of a delayed-release preparation of fenofibrate.

번역 견적 문의
고객상담월- 금 09 : 00 ~ 18 : 00
24시간  견적의뢰 가능 (일요일 제외)